You hit the nail on the head! Many see the RS as a

You hit the nail on the head! Many see the RS as a negative because of its reputation on the OTC. I’ve never heard someone give an equal comparison of a company that did a reverse split for the reason to uplist to the big boards to get institutional financing *but* whom also has strong fundamentals as FUSZ. I wish someone gave me a tech
Company as a comparison and not a biotech company because every time I get a biotech company as a comparison I always ask what makes this company so special.

Most companies on the OTC RS for the wrong reasons and that’s to hopefully survive a bit longer.

Essentially FUSZ can cancel the RS and can stay on the OTC and can do ok but then Rory won’t be able to bring the business to the next level they want to bring it to and that’s a multi billion dollar business. Staying on the OTC they won’t get the funding at a normal rate or any funding for that matter (we need multi millions in financing and not a few hundred thousands to grow the business and we need large financing from non toxic lenders like Kodiak and Oceanside but from JP Morgan) and they will be prone to the same manipulation we’ve been seeing the last 12-18 months by the MMS.